In sum, we have demonstrated that the CANK2A1/HMGA2/Bcl‐2/Bax axis modulates the sensitivity of cervical cancer cells to cisplatin, and potentially provides new therapeutic targets for overcoming chemoresistance in cervical cancer. The gene discussed is HMGA2; the disease is cervical carcinoma.